rs709158 — PPARG

Intronic PPARG variant in strong linkage disequilibrium with rs1175543; the G allele is associated with higher LDL-cholesterol and participates in multi-locus interactions affecting abdominal obesity, CRP, and metabolic trait variation.

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG rs709158 — A Haplotype Marker Linking Intronic PPARG Variation to Cholesterol and Metabolic Risk

Peroxisome proliferator-activated receptor gamma (PPARγ11 PPARγ
PPARγ is a nuclear receptor that acts as the master transcriptional regulator of adipogenesis — the process by which preadipocytes differentiate into fat cells — and governs fatty acid uptake, lipid storage, and insulin sensitivity across adipose, liver, and muscle tissue) is one of the most metabolically consequential proteins in the human body. rs709158 is a common intronic variant in PPARG, sitting at GRCh38 chr3:12,421,677 (A>G substitution, plus strand). Although it does not change any amino acid, it sits within a haplotype block with well-documented associations with cholesterol levels, LDL-C, and inflammatory markers across multiple independent cohorts.

The Mechanism

rs709158 resides deep in an intron of PPARG and has no known direct effect on protein structure. Its metabolic relevance is as a haplotype tag SNP: it is in very strong linkage disequilibrium22 very strong linkage disequilibrium
Linkage disequilibrium (LD) means two variants are so physically close on the chromosome that they are nearly always inherited together; D'=0.97 approaches perfect co-inheritance with rs1175543 (D' = 0.97) and in the same broader intronic haplotype block as rs1797912 and rs12490265. This tight LD means rs709158 tags a distinct functional haplotype configuration that influences PPARγ pathway output — likely through effects on intronic splicing regulation, chromatin accessibility, or nearby enhancer activity — rather than through a direct coding change. The G allele (minor allele, global frequency ~27%) co-segregates with haplotypes linked to higher LDL-cholesterol and elevated inflammatory tone, while the reference A allele represents the metabolically neutral population baseline.

The Evidence

A large prospective cohort of 9,364 Caucasians in Washington County, Maryland33 large prospective cohort of 9,364 Caucasians in Washington County, Maryland
Gallicchio et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality. PPAR Res, 2008 followed participants from 1989 to 2003 and found statistically significant age-adjusted associations between rs709158 and baseline total cholesterol levels. No associations with cardiovascular mortality or events were detected over the 14-year follow-up, suggesting the variant's influence is metabolic rather than directly cardioprotective or cardiotoxic.

A cross-sectional study in 820 Chinese Han individuals44 cross-sectional study in 820 Chinese Han individuals
Fan et al. Association and interaction of PPARα, δ, and γ gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population. Genet Test Mol Biomarkers, 2015 found that minor-allele carriers at rs709158 had significantly higher LDL-cholesterol levels (p < 0.05) after covariate adjustment, and that rs709158 participated in multi-locus PPAR interactions producing cumulative LDL-C elevation. The minor allele here is the G allele.

A study of 643 Chinese Han subjects55 study of 643 Chinese Han subjects
Gu et al. Effect of obesity on the association between common variations in the PPAR gene and C-reactive protein level. Endocrine, 2015 showed that rs709158 was significantly associated with elevated CRP in normal-weight individuals, and that this effect was modified by weight status — overweight and obese individuals showed a different genetic association pattern, indicating gene-environment interaction at this locus.

The Matsuo et al. calorie restriction trial66 Matsuo et al. calorie restriction trial
Matsuo et al. PPARG genotype accounts for part of individual variation in body weight reduction in response to calorie restriction. Obesity (Silver Spring), 2009 enrolled 95 middle-aged Japanese women in a 14-week calorie restriction intervention and found that rs709158 was among six PPARG SNPs significantly associated with inter-individual variation in the degree of body weight reduction — suggesting that this intronic PPARG haplotype influences adipose tissue remodeling during negative energy balance.

Evidence remains at the emerging level: most findings come from Chinese Han cohorts of modest size (n = 643–820), the Caucasian cohort (Gallicchio) found a cholesterol association but did not report individual effect sizes, and no large meta-analysis has specifically examined this variant.

Practical Actions

For G-allele carriers — particularly AG and GG genotypes — the consistent direction across independent cohorts is toward higher LDL-cholesterol and elevated baseline CRP. These signals translate into genotype-specific monitoring and dietary fat composition adjustments targeting LDL-C. For AA homozygotes, the reference haplotype represents the metabolically neutral population baseline at this locus, and no specific intervention is indicated by this SNP alone.

Interactions

rs709158 is in very strong LD (D' = 0.97) with rs1175543, a closely positioned intronic PPARG variant studied for metabolic syndrome risk. Because the two variants almost always co-segregate, they largely tag the same haplotype signal. rs709158 also participates in documented multi-locus interactions with other PPAR-family variants (PPARA, PPARD) affecting abdominal obesity (Ding 2012, PMID 22944052) and ApoA1/ApoB100 ratios (Hai 2015). The canonical PPARG coding variant rs1801282 (Pro12Ala) exerts independent and stronger effects on insulin sensitivity through direct alteration of receptor structure; rs709158 and rs1801282 effects are additive rather than redundant.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Common PPARG Background Normal

Reference PPARG haplotype — metabolically neutral at this locus

The AA genotype is homozygous for the GRCh38 plus-strand reference allele at chr3:12,421,677. Being an intronic variant, rs709158 itself does not alter any protein sequence — its metabolic relevance is entirely as a haplotype marker. The A allele co-segregates with the PPARG haplotype configurations that showed the lowest LDL-C associations in the Fan 2015 study and the lowest CRP associations in the Gu 2015 study. Because this is an emerging-evidence finding from cohorts of moderate size, AA genotype should be interpreted alongside rs1801282 (Pro12Ala), which carries far stronger and more established evidence for insulin sensitivity effects, and rs1175543, which tags a nearly identical haplotype signal.

AG Partial G-Haplotype Carrier Intermediate

One copy of the G allele — modestly elevated LDL-C and CRP signal

The AG heterozygote state means one chromosome carries the G-tagged haplotype and the other carries the reference A haplotype. Since the effect appears additive, AG carriers sit between AA (no excess risk) and GG (full effect) on the LDL-C and CRP dimensions. The calorie restriction study by Matsuo 2009 found rs709158 among six PPARG SNPs affecting weight loss response, suggesting this haplotype also modulates fat mobilization efficiency during energy restriction. No published study has characterized the AG heterozygote separately from GG in terms of effect magnitude — the additive assumption is a standard inference for intronic PPARG variants that do not show dominant effects in the literature.

GG Homozygous G-Haplotype High Risk

Two copies of the G allele — higher LDL-C and inflammatory risk signal

GG homozygosity means both chromosome copies carry the G-tagged PPARG haplotype, producing the maximum additive effect at this locus. The Fan 2015 study in 820 Chinese Han individuals found minor-allele carriers at rs709158 had statistically elevated LDL-C; the Gu 2015 study (643 subjects) found the rs709158 variant significantly associated with CRP in normal-weight individuals, with the effect modified by obesity status — suggesting the genetic signal is most clearly expressed before weight gain has already elevated inflammation. The Ding 2012 study identified rs709158 in a five-locus gene-gene interaction model for abdominal obesity risk, and the Hai 2015 study found it in an eight-locus model affecting ApoA1/ ApoB100 ratios. These multi-locus findings indicate that GG homozygotes who also carry risk alleles at other PPAR-family variants accumulate compounding lipid-metabolic disadvantages. Note that all findings remain at the emerging evidence level — the studies are modest in size, largely confined to East Asian cohorts, and no large-scale meta-analysis has isolated this variant's effect size with precision.